Prevents Pneumocystis jirovecii pneumonia (PCP). ANDA 202960, held by Amneal Pharmaceuticals. Atovaquone.
As of Nov 21, 2026, ANDA 202960 (Atovaquone), held by Amneal Pharmaceuticals, was first approved by FDA on Mar 18, 2014, with 5 approved supplements and 0 published complete response letters.
Atovaquone oral suspension is a quinone antimicrobial drug indicated for: Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. Limitations of Use: Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] >45 mm Hg) with atovaquone oral suspension has not been studied. The efficacy of atovaquone oral suspension in subjects who are failing therapy with TMP-SMX has also not been studied. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 18, 2014 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Atovaquone750MG/5ML ยท suspension;oral | Atovaquone | Rx |
| Sep 24, 2026 | Supplement 23Labeling ยท Standard review | Approved | None posted |
| Sep 20, 2019 | Supplement 9Labeling ยท Standard review | Approved | None posted |
| Sep 20, 2019 | Supplement 7Labeling ยท Standard review | Approved | None posted |
| Dec 21, 2018 | Supplement 5Labeling ยท Standard review | Approved | None posted |
| Dec 21, 2018 | Supplement 2Labeling ยท Standard review | Approved | None posted |
| Mar 18, 2014 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. โWhat FDA's review saysโ is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters